title: Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran--feasibility study.
abstract: Institutional review board approval and informed consent were obtained. The feasibility of magnetic resonance (MR) imaging with impaired clearance of ferucarbotran to visualize ablated liver parenchyma surrounding a tumor (ablative margin [AM]) was evaluated after radiofrequency (RF) ablation of the liver. Twenty-one patients with hepatocellular carcinomas underwent RF ablation 2-7 hours after ferucarbotran-enhanced MR imaging. On unenhanced T2*-weighted images acquired after 3-5 days, AMs appeared as hypointense rims. The AM status was related to incidence of residual or recurrent tumors. This technique is feasible for visualization of AM and prediction of residual or recurrent tumors after RF ablation of the liver.
authors.affiliation: Department of Diagnostic and Interventional Radiology, Institute of Clinical Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan. moriken@md.tsukuba.ac.jp
authors.forename: Kensaku
authors.initials: K
authors.lastname: Mori
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Fukuda
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Asaoka
authors.forename: Takuya
authors.initials: T
authors.lastname: Ueda
authors.forename: Akira
authors.initials: A
authors.lastname: Kunimatsu
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Nasu
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Fukunaga
authors.forename: Yukio
authors.initials: Y
authors.lastname: Morishita
authors.forename: Manabu
authors.initials: M
authors.lastname: Minami
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000601:surgery*; D003287:Contrast Media; D003911:Dextrans; D005240:Feasibility Studies; D005260:Female; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron; D008113:Liver Neoplasms / Q000473:pathology* / Q000601:surgery*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D010087:Oxides; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D025321:Surgery, Computer-Assisted / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide